Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Contenido no disponible. Consulta la fuente original.
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.